Background: In most parts of the world, curatively intended treatment for esophageal cancer includes neoadjuvant therapy, either with chemoradiotherapy or chemotherapy alone, followed by esophagectomy. Currently 18F-FDG positron emission tomography/computed tomography (PET/CT) is used for preoperative disease staging, but is not well established in the evaluation of neoadjuvant treatment. Purpose: To evaluate changes in PET parameters in relation to the histological primary tumor response in the surgical specimen in patients randomized to neoadjuvant chemoradiotherapy or chemotherapy. Material and Methods: Patients were randomized between either neoadjuvant chemotherapy or chemoradiotherapy followed by esophagectomy.18F-FDG PET/CT exams were conducted at baseline and following neoadjuvant treatment. Standardized uptake ratio (SUR) values were measured in the primary tumor and compared as regards histological responders and non-responders as well as different treatment arms. Results: Seventy-nine patients were enrolled and 51 were available for analysis. A significant rate of SUR reduction was observed (P ¼ 0.02) in the primary tumor in histological responders compared to non-responders. Changes in SUR were significantly greater in responders following chemoradiotherapy (P ¼ 0.02), but not following chemotherapy alone (P ¼ 0.49). There was no statistically significant difference in SUR in patients with a complete histological response compared to those with a subtotal response. Conclusion: Our results are similar to those of previous studies and show that changes in the rate of SUR can be used reliably to differentiate histological responders from non-responders after neoadjuvant treatment with either chemoradiotherapy or chemotherapy. Limitations of current PET technology are likely to restrict the possibility of accurately ruling out limited residual disease.
Introduction
Cancer of the esophagus and gastroesophageal junction (GOJ) is associated with a poor prognosis and the overall five-year survival rate is around 15% (1, 2) .
The addition of neoadjuvant chemotherapy (NACT) or chemoradiotherapy (NACRT) before esophagectomy has been shown to improve long-term survival when compared to surgery alone in patients with cancer of the esophagus or GOJ (3) (4) (5) . Three randomized controlled trials (RCT) comparing NACT and NACRT have shown a higher degree of histologic response after CRT, but no difference in long-term survival. Moreover, the ideal regimen of neoadjuvant treatment remains unclear (6) .
Postoperative pathological staging by semiquantitative Tumor Regression Grading (TRG) of remaining cancer cells in the specimen following NACRT has been shown to be an independent and strong predictor of disease progression and long-term survival of patients with cancer of the esophagus or GOJ (7) . A complete absence of remaining cancer cells is classified as a complete histological response (pCR) and is associated with the best prognosis, but partial histological response is also a predictive factor for better long-term survival (7) (8) (9) .
The association between histological response and overall survival may, however, depend on histologic type, i.e. adenocarcinoma (AC) or squamous cell cancer (SCC). The recently published NeoRes RCT of NACT versus NACRT could not demonstrate a relationship between pCR and survival, and a there was even a trend to poorer long-term survival among patients with AC, possibly as a result of treatmentrelated mortality and the inverse for SCC (10) .
It has been reported that pCR of the primary tumor may occur in up to half of the cases with SCC following NACRT. The rate of pCR in AC is lower (3, 11) . Complete response is also more often achieved following NACRT compared to NACT (10) .
Conversely, patients who show little or no histological response to neoadjuvant treatment might not benefit from it and may, in fact, be better suited for direct esophagectomy.
Clinical evaluation of histological response to neoadjuvant treatment presents a formidable challenge and there is a great need for refined diagnostic approaches. Even when combining several modalities, i.e. endoscopy, endoscopic ultrasound (EUS), computed tomography (CT), and positron emission tomography (PET)/CT, the accuracy remains insufficient for reliable restaging and identification of patients with pCR where surgery could hypothetically even be avoided. This important question is currently addressed in a study where patients with SCC and a high likelihood of pCR based on PET/CT imaging and endoscopic assessment are randomized to esophagectomy or active observation, followed by rescue esophagectomy in case of recurrence (12) .
Preoperative staging of esophageal or GOJ cancer using 18Fluorodeoxyglucose (18F-FDG) PET/CT is clinically widely established primarily for the added value in detecting sites of nodal and distant metastasis (13) . It is in the setting of preoperative restaging that evaluation using 18F-FDG PET/CT might be of further use.
Several studies have been conducted in order to assess the potential role of PET/CT in predicting TRG. Results have, however, been inconsistent (14) (15) (16) (17) (18) . When reviewing the literature, it is apparent that identifying the optimal PET parameters for the assessment of histological tumor regression has presented an obstacle.
Several studies have been conducted on changes in SUV max or ÁSUV as potential predictors of TRG, but a recent study has shown that variations in standardized uptake ratio (SUR) may be a more accurate predictor for TRG (19) .
Weber et al. pioneered the concept of using 18F-FDG PET as a potential tool in predicting histological response in patients with esophageal cancer. Using receiver operating characteristic (ROC) analysis, a cut-off value reduction of SUV max was found to be a highly accurate predictor of histological response (18) .
Encouraged by these results and using the same cutoff value, the MUNICON study was conducted (14) . Patients with esophageal AC were included. Following induction NACT, more than half of the metabolic responders were found to be histologic responders. The authors were, however, not able to distinguish pCR from sub-total histological response.
One large retrospective study of stage II-III cancer of the esophagus undergoing NACRT showed, even though no significant difference in the absolute decrease of SUV max between baseline and follow-up could be found in correlation with TRG, a significant difference in the rate of SUV max reduction ([follow-up SUV maxbaseline SUV max ]/baseline SUV max ) was observed (15) .
The most apparent potential confounder in the disparate results is the use of external-beam radiation in the neoadjuvant therapy. This is associated with a high incidence of radiation esophagitis, which is prone to increase the metabolic activity in the tumor area.
Supporting this argument, studies in which only chemotherapy and no radiation were used have shown a more consistent association between PETresponse and TRG (20) .
To date, no RCTs comparing nCRT and nCT addressing the association between PET parameters and histological primary tumor response have been published.
The primary aim of this study was to evaluate changes in PET parameters, and in particular the previously rarely used SUR value in relation to postoperative TRG of the primary tumor in esophageal or GOJ cancer patients randomly assigned to either NACRT or NACT.
Material and Methods

Patient population
The study population consisted of a subgroup from our academic center within the RCT Neoadjuvant Chemotherapy versus Chemoradiotherapy in Resectable Cancer of the Oesophagus and Gastric Cardia (NeoRes) (10) . The NeoRes trial recruited patients at nine hospitals in Sweden and Norway during 2006-2013. The primary aim was to evaluate whether NACRT more often resulted in a complete histological response (pCR) following resection in comparison to NACT alone in patients with resectable carcinoma of the esophagus (AC or SCC) or type I or type II GOJ cancer, according to the Siewert classification of GOJ cancer (21) .
Patients were eligible with histologically confirmed tumors at stage T1-T3, any nodal stage and non-distant metastatic SCC or AC of the esophagus or GOJ where there was intent of curative resection. Further inclusion criteria were patients aged 75 years and patients who were considered fit for esophagectomy and with performance status, renal and haematological status permitting chemotherapy. In order to maintain PET data consistency, only patients treated at our academic center were included in this analysis. Patients were excluded who withdrew participation out of personal choice (n ¼ 11), were not allotted treatment due to human error (n ¼ 2), had severe adverse effects to neoadjuvant treatment (n ¼ 3), had unclear reasons (n ¼ 1), were not resected due either to disease progression or co-morbidity (n ¼ 10), or due to tumor non-avidity at baseline as well at follow-up (n ¼ 1).
Treatment arms
The study participants were randomized either to NACRT followed by surgical resection (three cycles of Cisplatin/oxaliplatin-5-FU þ 40 Gy given in fractions) or NACT followed by resection (three cycles of Cisplatin/oxaliplatin-5-FU). PET/CT parameters were assessed before and after treatment using whole-body 18F-FDG PET/CT.
Esophagectomy was performed 4-6 weeks after the completion of neoadjuvant treatment in both treatment arms. Forty-one patients were randomized to the NACRT group and 39 were randomized to the NACT group.
PET/CT protocol
PET/CT examinations were conducted according to a standardized study protocol at the Department of Nuclear Medicine at our academic center. Imaging was conducted using a Biograph 64 True Point V PET/CT system (Siemens Medical Solutions, Erlangen, Germany). A total of 4 Mbq per kg bodyweight was administered intravenously 60 min between FDG administration and PET/CT scan with 4 min/bed position. Non-contrast-enhanced CT scan and CT data were used for attenuation correction. OSEM PET reconstructions were made using four iterations and eight subsets and a matrix size of 168 Â 168. Baseline examinations were performed as a part of routine pretreatment staging. Follow-up PET/CT scans were obtained following conclusion of neoadjuvant treatment and before surgery. Follow-up exams also served as part of clinical evaluation of neoadjuvant treatment. Interim PET/CT scans were obtained after the initial induction chemotherapy in both treatment arms.
Image assessment
A single radiologist/resident in nuclear medicine and a senior nuclear medicine physician/radiologist reviewed the PET/CT images. PET and CT images were reviewed in separate as well as fused stacks using the HERMES viewing software (Hermes Medical Solutions, Stockholm, Sweden) for better definition of the lesion borders. Delineation of the primary tumor site was performed using visually assessed hand-drawn ROIs in transversal, coronal, and sagittal orientations. Within the volume of interest (VOI) obtained, the primary tumor was subsequently delineated from surrounding tissues using a standardized uptake value (SUV) threshold of 2.0. This process is illustrated in Fig. 1 . SUV max was defined as the SUV of the voxel with the highest value within the lesions. To avoid confounders at SUV, quantification between patients (differences in metabolic status, FDG availability, time between FDG administration and scan, etc.), the tissue to blood SUR was scored. As previously demonstrated by van den Hoff et al. for irreversible tracer uptake, SUR correlates well with the net FDG tissue uptake at late timepoints (22) . In our study, SUR values were calculated as the ratio between SUV max of the tumor and SUV mean of a 1-cm 3 VOI placed within the mediastinal blood pool. All PET/CT assessment was performed completely blinded to treatment allocation and other clinical data. Initially measurements of volumetric PET parameters (metabolic tumor volume and total lesion glycolysis) were planned. However, nine out of 51 patients were treated with esophageal stents following baseline examination but before follow-up examination due to dysphagia with associated changes of the anatomical conditions in the affected area and for this reason these measurements were abandoned.
Quantification of PET parameters in response to neoadjuvant treatment
To quantify the response to neoadjuvant treatment, a simple linear model of the variation of the SUR with time between baseline to follow-up examination was obtained for each patient. From this linear model, the SUR rate of change in units per day SUR (days -1 ) was used as a predictor of increases in tumor metabolism (for positive rates) or decreases in tumor metabolism (for negative rates).
Postoperative histological grading
A single senior pathologist at our academic center performed postoperative histological grading following esophagectomy. The pathologist was blinded with regard to treatment allocation. Specimens were assessed using TRG grading describing the ratio of tumor cells to fibrotic cells, as suggested by Chirieac et al. (7) . TRG was graded as follows: 1 ¼ no remaining tumor cells; 2 ¼ 1-10% tumor cells; 3 ¼ 11-50% tumor cells; and 4 ! 50% tumor cells. TRG 1 and TRG 2 were considered to be histological responders, while TRG 3 and TRG 4 were considered to be non-responders.
Statistics
A one-way ANOVA, with P < 0.05, was used to test whether the rate of change in SUR can be used as predictor for histological treatment response: first, for pooled treatment arms; and second, for each treatment arm separately.
Furthermore, and again using a one-way ANOVA test with P < 0.05, we also tested for differences in the rate of change of SUR: first, between treatment arms for pooled tumor types; second, between treatment arms for both histological tumor types (AC and SCC); and third, between between ypT-stages (postneoadjuvant pathological stages).
Ethics approval and consent to participate
This study was approved by our regional ethical review board as well as by the radiation safety board at our academic center. Written consent was required for participation in this study.
Results
Seventy-nine patients were enrolled and 51 were available for analysis (Fig. 2) . Analysis was made by intention to treat.
The treatment groups were well balanced with regard to age, sex, and tumor characteristics ( Table 1 ). The mean time between baseline and follow-up PET/CT was similar in responders (80.7 AE 13.9 days) compared to non-responders (75.8 AE 29.5 days) (P ¼ 0.6). We found no correlation between the number of days elapsed between conclusion of neoadjuvant therapy and reduction of SUR (data not shown).
The mean time between conclusion of neoadjuvant therapy and follow-up PET/CT was also similar in responders (15.7 AE 9.2 days) compared to non-responders (17.9 AE 24.9 days) (P ¼ 0.5). The mean rate of SUR change (days -1 ) was -0.048 AE 0.049 and -0.017 AE 0.041 for pooled NACRT and NACT responders and pooled non-responders, respectively (P ¼ 0.02). PET variable observations and histological responses in the two treatment arms are presented in Table 2 .
Changes in SUR from baseline to follow-up examination are presented in Table 3 . The rate of reduction of SUR in histological NACRT responders was statistically significantly higher than that observed in histological non-responders (P ¼ 0.02). The rate of reduction of SUR in histological NCT responders was not significantly different from that observed in histological nonresponders (P ¼ 0.49). Neoadjuvant treatment with NACRT led to a significantly higher rate of reduction in tumor SUR compared to patients treated with NACT (P ¼ 0.04). There were no statistically significant differences in the rate of SUR changes by tumor type (AC or SCC) in either treatment arm (P > 0.1 for all combinations) ( Table 4) .
There were no significant differences in the rate of reduction of SUR when comparing TRG 1 to TRG 2-4 in a pooled analysis including AC and SCC (data not shown). There were no significant differences in the rate of reduction of SUR in regard to ypT-stage (P ¼ 0.87).
Analysis of interim PET/CTs after the first chemotherapy cycle was abandoned due to the high rate of missing examinations (26/51, 51%).
Discussion
This cohort study within a RCT of NACRT versus NACT shows a significantly higher rate of reduction Values are presented as n (%) unless otherwise specified.
of tumor SUR in histological responders when compared to non-responders. There was a significantly higher rate of reduction of SUR in responders following NACRT, but not in responders following NACT. A significantly higher rate of reduction of SUR was also observed in general following NACRT when compared to NACT, which corresponds to specimen TRG.
When stratified, there were no statistically significant differences in the rate of change of SUR values when comparing treatment arms with regard to histological tumor type. TRG grading does not take the volume of the tumors into account; however, we did not observe any significant changes in SUR in regard to ypT-stage.
By observing the rate of change in tumor SUR rather than changes in SUV max or SUV mean , some of the inherently imprecise measurements of PET parameters may be avoided. We believe that the SUR parameter theoretically offers a more reliable reflection of pathophysiological changes in tumor metabolism.
Results from previous studies on changes in PET parameters following neoadjuvant treatment have been inconclusive (14) (15) (16) (17) (18) . These studies have, however, for design purposes either been conducted retrospectively or have included either several different courses of neoadjuvant therapy or a single course of neoadjuvant therapy.
Our findings are in line with previous studies in that we observed a significant rate of reduction of SUR in patients with histological response in comparison with histological non-responders. The same is true concerning the significantly higher rate of SUR reduction in responders following NACRT. Our interpretation of the greater reduction of SUR in the NACRT arm mirrors the impact on tumor metabolism resulting from this more aggressive treatment course. It also correlates with the higher degree of histological response in this treatment arm.
The fact that we did not observe any significant differences in the rate of SUR reduction in responders following NACT is, however, not consistent with previous findings. Previous studies have reported a Table 2 . PET variable observation and histological response. significant reduction in SUV values following NACT (14, 18, 23) . One explanation for this may be the low frequency of histological responders in the NACT treatment arm (3/26, 12%). In the NeoRes trial, histological response was observed in 12/91 (15%) of patients in the NACT arm. It is, nevertheless, possible that the smaller population in this study could obscure a potential difference, i.e. a type 2 statistical error. Moreover, no correlation was observed with carcinoma type (AC or SCC) and changes in SUR in responders when compared to non-responders. When performing this subgroup analysis, it is apparent that the low study power may have affected the lack of significant findings. Changes in SUR could not be used in order to differentiate pCR from subtotal response. The question of whether this observation is true is the most difficult to address when reviewing similar studies. In our study, only 6/51 (12%) of patients achieved pCR, which is at the lower end of the spectrum when compared to the current literature, and it is possible that a larger sample size may affect this relation. Meanwhile, pCR was achieved in 29/181 (16%) of patients in the whole NeoRes population.
Some previous studies have defined levels of reduction of SUV max by ROC analysis and found associated high likelihoods of pCR (16, 24) . The uncertainty when determining a significant level of change in PET metrics is the reason why no such analysis was made in our study. Rather, we have undertaken a project to make an objective assessment of the predictive value of rate of change of SUR and histological response.
Other retrospectively designed studies have opted to investigate post neoadjuvant PET-negative tumors in relation to histological response. They have shown an inability to reliably rule out residual tumor cells in a PET-negative tumor with false-negative rates of 17.9% (13/73) (25) to 29.5% (5/17) (26) . One large retrospective cohort study of patients with AC of the esophagus and GOJ, which was conducted recently, gives a different picture (17) . In this study, no significant correlation between FDG-PET complete response and pCR was found. Furthermore, there were no significant differences in ÁSUV max or SUR at baseline or follow-up before and after NACRT to discriminate pCR from sub-complete histological response.
Concerning current PET/CT technology, it is apparent that the inherent relatively low spatial resolution of PET/CT is a limiting factor as regards detecting small residual disease.
In a clinical setting, the utility of predicting pCR would likely prove valuable. Patients with pCR could arguably be monitored in a watchful waiting setting and unnecessary esophagectomy might perhaps be avoided. The clinical value in the post neoadjuvant differentiation of pCR and subtotal histological response from non-responders would improve the prognostic evaluation of treatment response, where TRG2 likely benefits from neoadjuvant treatment but where TRG 3 and TRG 4 would arguably benefit from surgery alone.
Identifying the most reliable PET parameters remains an obstacle in the clinical implementation of 18F-FDG PET/CT in response evaluation of esophageal cancer. The same applies to the lack of universally accepted minimal standards of care.
The strength of this study is the prospective design and randomization of patients with a populationrepresentative histological carcinoma type to one of two well-defined regimens of neoadjuvant therapy. The main weakness of the study is the small patient pool, which may have had an effect on a lower than expected frequency of histological responders in the NACT group as well as in comparison to larger retrospective studies with similar aims. Furthermore, due to epidemiological and clinical factors, there is a considerable heterogenicity in histological subtype and T-stage in the patient population.
In conclusion, this study shows that sequential 18F-FDG PET/CT can discriminate histological responders from non-responders following neoadjuvant therapy with NACRT or NACT. Furthermore, a decrease in the rate of SUR appears to be an accurate predictor of histological response. 18F-FDG PET/CT itself cannot discriminate pCR from non-pCR. Advances in PET technology and a multimodality approach (PET/CT, EUS, endoscopy, genetic analysis, novel biomarkers) are required in order to improve the evaluation of treatment response.
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